Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Niacin/Laropiprant in Statin-Treated CHD Patients
NCT01126073Phase 4Completed
- Sponsor
- University Medical Centre Ljubljana
- Start
- Sep 2010
- Primary completion
- Oct 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in coronary heart disease (CHD) comparing Niacin/Laropiprant with Placebo (2 arms). Primary endpoint: Endothelial dependant dilatation of the arterial wall at 12 weeks. Started Sep 2010; status: completed.
02
Drugs
laropiprant
03
Conditions
coronary heart disease (CHD)
Beyond the preview
Go deeper on NCT01126073.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01126073.